Markets & Stocks

Stock quotes, market indicators and the latest market news.

Market Summary Market News Stock Quotes Market Movers

Recent Quotes

View Full List

My Watchlist

Create Watchlist

Indicators

Dow Jones Industrial Average

Local Stocks

Markets:

Overview

News

Currencies

International

Treasuries

Valneva SE - American Depositary Shares (NQ:VALN)

5.715 +0.085 (+1.51%)

Delayed Quote Updated: 10:30 AM EST, Nov 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Valneva SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Why Pfizer Stock Was so Healthy in August ↗

September 08, 2026

The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter.

Via The Motley Fool

Topics Intellectual Property

Valneva (VALN) Q2 2026 Earnings Call Transcript ↗

August 20, 2026

Restructuring efforts and Lyme vaccine regulatory timeline take center stage.

Via The Motley Fool

Topics Earnings

Valneva Q2 Earnings Call Highlights ↗

August 13, 2026

Valneva (NASDAQ:VALN) reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and...

Via MarketBeat

Topics Earnings

Valneva Stock Tumbles 19% After FDA Suspension Of Ixchiq License In US, Wall Street Divided On The Impact ↗

August 25, 2025

Via Stocktwits

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Insights Ahead: Valneva's Quarterly Earnings ↗

May 06, 2025

Via Benzinga

4 Analysts Have This To Say About Valneva ↗

February 19, 2025

Via Benzinga

Valneva Q1 Earnings Call Highlights ↗

May 13, 2026

Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme...

Via MarketBeat

Topics Earnings

Why Wolfspeed Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket ↗

September 30, 2025

Via Benzinga

EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

August 26, 2025

Via Benzinga

Crude Oil Surges 2%; Chicago Fed National Activity Index Edges Lower in July ↗

August 25, 2025

Via Benzinga

Topics Economy

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 25, 2025

Via Benzinga

Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday ↗

August 25, 2025

Via Benzinga

Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US ↗

August 25, 2025

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S. sales and regulatory review.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 25, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 13, 2025

Via Benzinga

GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday ↗

July 23, 2025

Via Benzinga

MP Materials, CoreWeave, Trade Desk And Other Big Stocks Moving Higher On Tuesday ↗

July 15, 2025

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026 ↗

June 05, 2025

Valneva reports positive six-month data for Ixchiq in children, supporting a full dose approach ahead of a Phase 3 trial set for early 2026.

Via Benzinga

US Health Agencies Recommend Pausing Valneva's Chikungunya Vaccine For Older Adults After Adverse Events ↗

May 12, 2025

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including deaths, trigger a new safety assessment.

Via Benzinga

Topics Death

12 Analysts Assess Valneva: What You Need To Know ↗

April 15, 2025

Via Benzinga

Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine ↗

April 14, 2025

Valneva's chikungunya vaccine Ixchiq receives Brazil approval, enabling expanded trials and access across Latin America and endemic regions.

Via Benzinga

Lamb Weston Posts Better-Than-Expected Results, Joins Sanofi And Other Big Stocks Moving Higher On Thursday ↗

April 03, 2025

Via Benzinga

Breaking Down Valneva: 6 Analysts Share Their Views ↗

March 21, 2025

Via Benzinga

Earnings Scheduled For March 20, 2025 ↗

March 20, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 31, 2025

Via Benzinga

Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot ↗

January 21, 2025

Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions.

Via Benzinga

Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday ↗

December 19, 2024

Via Benzinga

Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults ↗

December 03, 2024

Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.